Navigation Links
Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY

te, http://www.emisphere.com.

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615) filed on March 5, 2007.

CONTACT: Investor Relations, Stewart Siskind of Emisphere Technologies,Inc., +1-914-785-4742; or Media, Dan Budwick of BMC Communications,+1-212-477-9007 ext. 14, for Emisphere Technologies, Inc.

Web site: http://www.emisphere.com/

Ticker Symbol: (NASDAQ-NMS:EMIS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:6/3/2015)... 2015 RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering and developing innovative therapeutics, primarily ... today announced that it received a Notice of ... Trademark Office (USPTO) on its novel, self-delivering ... Interference in Ocular Indications," covers methods of ...
(Date:6/3/2015)... GAITHERSBURG, Md. , June 3, 2015  GenVec, ... collaboration with Dr. David T. Curiel and ... University at St. Louis (WUSTL).  ... Center and the Cancer Biology Division within the Department ... GenVec and the WUSTL team will create modified versions ...
(Date:6/3/2015)... , June 3, 2015  Armetheon, Inc., ... drugs for cardiovascular diseases, today announced that ... appointed Chief Executive Officer, effective immediately. Dr. Kakkar ... global, high-growth enterprises, with a successful track record ... human health. With expertise that includes the development ...
Breaking Medicine Technology:RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 2RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 3RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 4GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 2GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 3GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 4Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 2Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 3Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 4
... Oct. 26 Accuray,Incorporated (Nasdaq: ARAY ), ... today that the company is partnering with The ... Houston, Texas to launch a prospective,clinical study to ... in the study will be randomly assigned to ...
... announces data presented at AACR-NCI-EORTC ... ... (CTI) (Nasdaq and MTAX: CTIC) and Systems Medicine, LLC (SM), a,wholly-owned ... candidates during the 19th annual AACR-NCI-EORTC Symposium. "These studies show ...
Cached Medicine Technology:M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients 2M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients 3M. D. Anderson Cancer Center to Lead Study of Surgery vs. CyberKnife(R) Radiosurgery for Operable Lung Cancer Patients 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 5
(Date:6/3/2015)... MD (PRWEB) June 03, 2015 On the ... a $13 billion industry by 2020 ( click here ... Markets), computer scientists believe Baltimore has the talent ... industry in which genetic code and other biological data are ... cure disease. “Baltimore contains all the elements of a ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Array ... exchange technology, has announced that CEO Jonathan Rickert will ... 2015 on June 4, 2015. The session will ... technologies are disrupting traditional business models in health care, ... value. , WHAT: Digital Transformation and the Health ...
(Date:6/3/2015)... Justina Molzon, MS Pharm, JD will ... upcoming Annual Meeting. DIA’s Global Inspire Award program recognizes ... excellence, and commitment to service on a global scale. ... Service Award that recognizes the “Member of the Year” ... and who has contributed to the advancement of DIA’s ...
(Date:6/3/2015)... The panel of independent experts has spent weeks considering ... the awards presented tonight at TU-Automotive Detroit 2015. , ... best-of-the-best can now be revealed as: , Car Maker ... rivals aside by taking the coveted Car Maker of ... panel of expert judges., Stand out comments included: ...
(Date:6/3/2015)... 2015 According to an article published ... intercepted fake oxycodone pills which actually contained the potent ... look legitimate, and even sported the “A/215” imprint common ... consuming 30 mg oxycodone to be exceptionally critical of ... buy them illegally on the street. Fentanyl is an ...
Breaking Medicine News(10 mins):Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:TU-Automotive Awards 2015 winners revealed 2Health News:TU-Automotive Awards 2015 winners revealed 3Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3
... patients, study finds , MONDAY, March 8 (HealthDay News) ... they catch it early, but a new study suggests ... risk of developing the disease. , If their ophthalmologists ... in the eye won,t need to take prescription anti-glaucoma ...
... if parent had brain attack by 65, chances of same ... -- If your mother or father had a stroke by ... a stroke by that age are increased fourfold, U.S. researchers ... such as high blood pressure, obesity and smoking. These risks ...
... Virologists surprised to ... to be reactivated to an infectious form. , ... TAMPA, FL (PRWEB) February 20, 2010 -- Human herpesvirus 6 ... lasts for the rest of a person’s life. In a study funded by the ...
... , ... ... ... ...
... ... ... ... ...
... ... ... , ... , , ...
Cached Medicine News:Health News:Waiting Safe for Some at Risk of Glaucoma 2Health News:Stroke Risk Runs in the Family 2Health News:Stroke Risk Runs in the Family 3Health News:Infectious Virus Hides In Human Chromosomes During Latency And Can Be Passed From Parents To Their Children, 2Health News:Infectious Virus Hides In Human Chromosomes During Latency And Can Be Passed From Parents To Their Children, 3Health News:Infectious Virus Hides In Human Chromosomes During Latency And Can Be Passed From Parents To Their Children, 4Health News:Infectious Virus Hides In Human Chromosomes During Latency And Can Be Passed From Parents To Their Children, 5Health News:Chicago AIDS Advocates Launch Female Condom Campaign 2Health News:Chicago AIDS Advocates Launch Female Condom Campaign 3Health News:Chicago AIDS Advocates Launch Female Condom Campaign 4Health News:Chicago AIDS Advocates Launch Female Condom Campaign 5Health News:Chicago AIDS Advocates Launch Female Condom Campaign 6Health News:Chicago AIDS Advocates Launch Female Condom Campaign 7Health News:Chicago AIDS Advocates Launch Female Condom Campaign 8Health News:SCAN Health Plan Debuts the First Mobile Resource Center Built Specifically for Seniors 2Health News:SCAN Health Plan Debuts the First Mobile Resource Center Built Specifically for Seniors 3Health News:SCAN Health Plan Debuts the First Mobile Resource Center Built Specifically for Seniors 4Health News:SCAN Health Plan Debuts the First Mobile Resource Center Built Specifically for Seniors 5Health News:Highmark and its Employees Donate $161,686 for Haiti Disaster Relief Efforts 2Health News:Highmark and its Employees Donate $161,686 for Haiti Disaster Relief Efforts 3
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The Precedent establishes a new generation of revision hip stems....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Calcar replacement stems provide options for revision and trochanteric fractures. Revision hip surgery and trauma often require prosthetic designs that replace proximal medial calcar bone loss....
Medicine Products: